This database contains 457 studies, archived under the term: "drug therapy"
Click here to filter this large number of results.
Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias
We investigated whether angiotensin II receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACE-Is) are more strongly associated with Alzheimer’s disease (AD), vascular dementia (VaD), and other dementias, than other anti-hypertensive drugs. We conducted a nested case-control analysis within the UK general practice research database, with prospectively recorded anti-hypertensive prescribing data. We sampled cases aged […]
Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer’s disease and AD + DLB
Nelson, Peter T.,
Kryscio, Richard J.,
Abner, Erin L.,
Schmitt, Frederick A.,
Jicha, Gregory A.,
Mendiondo, Marta S.,
Cooper, Greg,
Smith, Charles B.,
Markesbery, William R.
Dementia can be caused by different diseases including Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), or both (AD + DLB). University of Kentucky AD Center pathologically-diagnosed AD and AD + DLB cases were evaluated who had three or more longitudinal antemortem mental status examinations (n = 156). Patients with important concomitant pathology (n = […]
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial
Cummings, J. L.,
Lyketsos, C. G.,
Peskind, E. R.,
Porsteinsson, A. P.,
Mintzer, J. E.,
Scharre, D. W.,
De La Gandara, J. E.,
Agronin, M.,
Davis, C. S.,
Nguyen, U.,
Shin, P.,
Tariot, P. N.,
Siffert, J.
IMPORTANCE: Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking. OBJECTIVE: To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation. DESIGN, SETTING, AND PARTICIPANTS: Phase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequential parallel comparison design with 2 consecutive 5-week treatment stages conducted August […]
Memantine in moderately-severe-to-severe Alzheimer’s disease: A postmarketing surveillance study
Clerici, Francesca,
Vanacore, Nicola,
Elia, Antonietta,
Spila-Alegiani, Stefania,
Pomati, Simone,
Da Cas, Roberto,
Raschetti, Roberto,
Mariani, Claudio
Background: Postmarketing surveillance studies (PMS) are an important tool for evaluating a drug’s effectiveness and safety in clinical practice. To our knowledge, no PMS on memantine monotherapy for moderately-severe-to-severe Alzheimer’s disease (AD) according to National Institute of Neurological and Communicative Disorders and Stroke—Alzheimer’s Disease and Related Disorders Association criteria has been conducted to date. Objective: […]
Use of anticholinergics and the risk of cognitive impairment in an African American population
Campbell, N. L.,
Boustani, M. A.,
Lane, K. A.,
Gao, S.,
Hendrie, H.,
Khan, B. A.,
Murrell, J. R.,
Unverzagt, F. W.,
Hake, A.,
Smith-Gamble, V.,
Hall, K.
Background: Anticholinergic properties of certain medications often go unrecognized, and are frequently used by the elderly population. Few studies have yet defined the long-term impact of these medications on the incidence of cognitive impairment. Methods: We report a 6-year longitudinal, observational study, evaluating 1,652 community-dwelling African American subjects over the age of 70 years who […]
Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial)
Ballard, Clive,
Brown, Richard,
Fossey, Jane,
Douglas, Simon,
Bradley, Paul,
Hancock, Judith,
James, Ian A.,
Juszczak, Edmund,
Bentham, Peter,
Burns, Alistair,
Lindesay, James,
Jacoby, Robin,
O'Brien, John,
Bullock, Roger,
Johnson, Tony,
Holmes, Clive,
Howard, Robert
Background: Good practice guidelines state that a psychological intervention should usually precede pharmacotherapy, but there are no data evaluating the feasibility of psychological interventions used in this way. Methods: At the first stage of a randomized blinded placebo-controlled trial, 318 patients with Alzheimer disease (AD) with clinically significant agitated behavior were treated in an open […]
Efficacy and safety of cerebrolysin in moderate to moderately severe Alzheimer’s disease: Results of a randomized, double‐blind, controlled trial investigating three dosages of cerebrolysin
Alvarez, X. A.,
Cacabelos, R.,
Sampedro, C.,
Aleixandre, M.,
Linares, C.,
Granizo, E.,
Doppler, E.,
Moessler, H.
Background: Cerebrolysin is a neuropeptide preparation mimicking the effects of neurotrophic factors. This subgroup analysis assessed safety and efficacy of Cerebrolysin in patients with moderate to moderately severe Alzheimer’s disease (AD) (ITT data set: N = 133; MMSE: 14–20) included in a dose‐finding study (ITT data set: N = 251; MMSE: 14–25). Results of the […]
Treatment with Huperzine A improves cognition in vascular dementia patients
Xu, Zhi-Qiang,
Liang, Xiao-Min,
Juan, Wu,
Zhang, Yuan-Feng,
Zhu, Chun-Xia,
Jiang, Xiao-Jiang
Unlabelled: In the present study, we tested the efficacy and safety of Huperzine A in treatment of mild to moderate vascular dementia (VaD). This was a randomized, double-blinded, placebo-controlled study with 78 patients with mild to moderate VaD. The participants were randomized to receive either vitamin C (100-mg bid) as placebo (n = 39) or […]